Get the Stockscreener App
5.46
0.18%
0.010
Pre-market:
5.42
-0.04
-0.73%
Curevac N V stock is traded at $5.46, with a volume of 1.42M.
It is up +0.18% in the last 24 hours and up +34.15% over the past month.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$5.45
Open:
$5.43
24h Volume:
1.42M
Relative Volume:
1.23
Market Cap:
$916.40M
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
9.9562
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
+0.18%
1M Performance:
+34.15%
6M Performance:
+29.69%
1Y Performance:
+66.97%
1-Day Range:
$5.415
$5.47
1-Week Range:
$5.36
$5.51
52-Week Range:
$2.37
$5.72
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.46 | 916.40M | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
CureVac: Pipeline pruning’s nasty effect - MarketScreener
CureVac N.V. (CVAC) Has Gained Over 16% In One Month. Here Is Why - Insider Monkey
Tesla chief Elon Musk teams up with Covid-19 player CureVac to build ‘RNA microfactories’ - Endpoints News
CureVac Announces Key Resolutions from Annual Shareholders Meeting - TipRanks
CureVac shareholders approve management changes and auditor By Investing.com - Investing.com UK
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Yahoo Finance
Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com
BioNTech SE Announces Acquisition of CureVac N.V. - TipRanks
Germany: BioNTech to acquire CureVac in all-stock transaction - Investors in Healthcare
BioNTech to Acquire CureVac in Strategic Move - TipRanks
CureVac agrees to pay Biontech termination fee Of $43.8 mln under specified circumstances - MarketScreener
5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga
BioNTech to Acquire CureVac in US$1.25 Billion All-Stock Transaction - Global Legal Chronicle
There's No Escaping CureVac N.V.'s (NASDAQ:CVAC) Muted Revenues Despite A 50% Share Price Rise - simplywall.st
CureVac’s SWOT analysis: mRNA pioneer’s stock faces pivotal year ahead By Investing.com - Investing.com Nigeria
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of - Bluefield Daily Telegraph
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BioNTech CureVac Acquisition Boosts Cancer Drug Pipeline - Industry Leaders Magazine
CureVac (CVAC) Receives Downgrade and Price Target Reduction fro - GuruFocus
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer - GlobeNewswire
Jefferies cuts CureVac stock rating to hold on BioNTech acquisition By Investing.com - Investing.com UK
BioNTech: Oddo BHF raises target price - marketscreener.com
BioNTech to buy CureVac in USD 1.25 billion all-stock deal - Medical Dialogues
CureVac Stock: BioNTech's Billion-Dollar Takeover Bid - sharewise
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
BioNTech (BNTX) to Acquire CureVac in $1.25 Billion All-Stock De - GuruFocus
CureVac (CVAC) Downgraded by Jefferies Analyst After BioNTech Acquisition Agreement | CVAC Stock News - GuruFocus
BioNTech Announces Strategic Transaction to Acquire CureVac in P - GuruFocus
BioNTech Announces Strategic Acquisition of CureVac - TipRanks
Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty - BioWorld MedTech
BioNTech to Acquire CureVac in $1.25B Deal - USA Herald
BioNTech's Acquisition Of CureVac Brings Complementary Method To Target Cancer (BNTX) - Seeking Alpha
5 Firms Guide $1.25B BioNTech, CureVac Oncology Deal - Law360
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, SOAR, MTWO on Behalf of Shareholders - MarketScreener
BioNTech to acquire CureVac in $1.25 billion all-stock deal By Investing.com - Investing.com South Africa
BioNTech to Acquire CureVac to Expand mRNA Cancer Therapies - N24.com.tr
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal - BioPharma Dive
Watkins Advises on BioNTech’s US$1.25 Billion Acquisition of CureVac - Latham & Watkins LLP
BioNTech Buys CureVac For $1.25 Billion In Stock Deal - Finimize
M&A News: BioNTech (BNTX) Acquires CureVac in $1.25 Billion Deal - TipRanks
CureVac Stock Soars on BioNTech Buyout - Schaeffer's Investment Research
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday - Benzinga
COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments - Investopedia
CureVac’s SWOT analysis: mRNA pioneer’s stock faces pivotal year ahead - Investing.com
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals - marketscreener.com
Vaccine developer with Boston HQ acquired for $1.25B - NBC Boston
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal year ahead By Investing.com - Investing.com India
Sector Update: Health Care Stocks Lean Lower Premarket Thursday - MarketScreener
BioNTech to Buy CureVac for $1.25 Billion for Cancer Boost - Bloomberg
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):